{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:40:50Z","timestamp":1782506450405,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clgc.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T03:07:36Z","timestamp":1589598456000},"page":"461-468.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Safety and Efficacy of Nivolumab in Patients With Advanced Non\u2013Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb\/IV CheckMate 374 Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Nicholas J.","family":"Vogelzang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Arrowsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Somer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjyot","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lingerfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph J.","family":"Hauke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Gunuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Schnadig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Veldhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Galamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Hool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brent","family":"McHenry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott S.","family":"Tykodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4329\/wjr.v8.i5.484","article-title":"Review of renal cell carcinoma and its common subtypes in radiology","volume":"8","author":"Low","year":"2016","journal-title":"World J Radiol"},{"key":"10.1016\/j.clgc.2020.05.006_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","article-title":"Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis","volume":"67","author":"Vera-Badillo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.05.006_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","article-title":"Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial","volume":"17","author":"Cella","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2020.05.006_bib6","series-title":"OPDIVO (nivolumab)","year":"2020"},{"key":"10.1016\/j.clgc.2020.05.006_bib8","first-page":"S41","article-title":"Three-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC)","volume":"2","author":"Sharma","year":"2017","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.clgc.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2020.05.006_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jval.2013.04.015","article-title":"Development and initial validation of the NCCN\/FACT symptom index for advanced kidney cancer","volume":"16","author":"Rothrock","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.clgc.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.05.006_bib13","first-page":"S32","article-title":"Safety of nivolumab in patients with clear cell (CC) or non-clear cell (NCC) renal cell carcinoma (RCC): results from the phase IIIb\/IV CheckMate 374 study","volume":"2","author":"McFarlane","year":"2017","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.clgc.2020.05.006_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/KCA-170019","article-title":"Non-clear cell renal cell carcinoma: current management and best practice","volume":"1","author":"Salgia","year":"2017","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.clgc.2020.05.006_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.06.002","article-title":"Safety and efficacy of nivolumab in patients with advanced clear cell renal cell carcinoma: results from the phase IIIb\/IV CheckMate 374 study","author":"McFarlane","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2020.05.006_bib16","article-title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B","volume":"27","author":"McDermott","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.05.006_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.037","article-title":"Molecular correlates differentiate response to atezolizumab (atezo)\u00a0+ bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Rini","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732030104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732030104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:03Z","timestamp":1761564843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732030104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S155876732030104X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2020.05.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Nivolumab in Patients With Advanced Non\u2013Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb\/IV CheckMate 374 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}